

Image-based modelling of inhaler deposition during respiratory exacerbation

Josh Williams^a, Jari Kolehmainen^b, Steve Cunningham^c, Ali Ozel^{a,*}, Uwe Wolfram^{a,*}

^a*School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, UK*

^b*Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey, USA*

^c*Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK*

Abstract

For many of the one billion sufferers of respiratory diseases worldwide, managing their disease with inhalers improves their ability to breathe. Poor disease management and rising pollution can trigger exacerbations which require urgent relief. Higher drug deposition in the throat instead of the lungs limit the impact on patient's symptoms. To optimise delivery to the lung, patient-specific computational studies of aerosol inhalation can be used. However in many studies, inhalation modelling does not represent an exacerbation, where the patient's breath is much faster and shorter. Here we compare differences in deposition of inhaler particles in the airways of a healthy male, female lung cancer and child cystic fibrosis patient. We aimed to evaluate deposition differences during an exacerbation with image-based healthy and diseased patient models. We found that during an exacerbation, particles progressing to the lower airways were distributed similarly to those inhaled during healthy breathing, but fewer in quantity. Throat deposits were halved in the healthy patient compared to the diseased patients under extreme inhalation, due to changes in the detailed shape of the throat. Our results identify that the modelled upper airway must be patient-specific, and an exacerbating profile tested for optimal measurement of reliever inhaler deposition.

Keywords: Drug delivery, Respiratory exacerbation, Patient-specific medicine, Dosimetry, Cystic fibrosis, Aerosol deposition

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding authors share last authorship

Email addresses: a.ozel@hw.ac.uk (Ali Ozel), u.wolfram@hw.ac.uk (Uwe Wolfram)

26 1. Introduction

27 More than one billion people worldwide suffer from asthma, cystic fibrosis, and other
28 chronic respiratory diseases (The Global Asthma Network, 2018), many experiencing dis-
29 tress and anxiety due to restrictions to activities and limited productivity (Dockrell et al.,
30 2007). These limitations are most prominent among the young and elderly (The Global
31 Asthma Network, 2018). One of the largest contributors to the diseased population is asthma,
32 which incurs an annual cost per patient of €1,700 and \$3,100 in Europe and the USA, re-
33 spectively (Nunes et al., 2017) from direct cost of treatment and indirect costs such as work
34 absence or decreased productivity (Katsaounou et al., 2018; Gruffydd-Jones et al., 2019).
35 Similar impacts are induced from cystic fibrosis, a highly common hereditary disease in the
36 UK, USA and Australia (Elborn, 2016). Consistent treatment in alignment with disease man-
37 agement plans are recommended to minimise symptoms (Ring et al., 2015), but adherence
38 is an issue in young patients (McQuaid et al., 2003) and many adults are purposely incon-
39 sistent to limit exposure to side-effects such as osteoporosis and cataracts (Dockrell et al.,
40 2007). Even in adherent patients, efficiency of the metered-dose inhaler varies greatly across
41 patients (Clark, 1995) as many (particularly children) experience difficulties in device tech-
42 nique (Usmani, 2019) due to the rapid spray of the drug. The issue of technique (patient
43 breathing pattern and coordination with device actuation) and differences in lung structure
44 are the main influences in drug delivery (Darquenne et al., 2016).

45 Optimisation of the medication deposition could be achieved through *in silico* analyses,
46 by providing the clinician information on the local deposition and therapeutic outcome. One
47 available deposition tool is the Multiple-Path Particle Dosimetry (MPPD) model (Anjilvel
48 and Asgharian, 1995; Asgharian et al., 2001). However this calculates deposition of ambient
49 particles (Borghardt et al., 2015), which does not mirror the physics of spray aerosol inhala-
50 tion (Longest et al., 2008). This issue has been recognised and a commercial counterpart to
51 predict deposition of pharmaceutical aerosols has been developed (Olsson and Bäckman,
52 2018). However, as the equations used are based on probabilistic 1D equations, similar to
53 that of MPPD, complex fluid phenomena and particle interactions cannot be included. Com-
54 parisons between 1D models and computational particle-fluid dynamics (CPFD) deposition
55 led Zhang et al. (2009) to observe significant differences in local deposition, attributed to

56 local flow. Flow and particle phenomena can be readily accounted for in CPFD by solving
57 equations governing the transport of air and particles (e.g. see (Sundaresan et al., 2018)).
58 Flow can be solved in airways extracted from medical images and particle properties can
59 represent inhaler particles to produce patient-specific deposition analyses. But with the
60 complexity of the flow regimes in the system creating demanding simulations and the mas-
61 sive number of respiratory patients, the benefit to cost of image-based modelling is an issue.
62 Work exists interpreting pharmaceutical deposition differences in adult patients (van Hols-
63 beke et al., 2018; Poorbahrami and Oakes, 2019; Poorbahrami et al., 2019), but only sparse
64 research models deposition in children. Existing children-focused image-based deposition
65 studies analyse the nasal cavity (Xi et al., 2011, 2012) or central airways (Das et al., 2018;
66 Oakes et al., 2018). To move towards enhanced treatments for all ages, a study consider-
67 ing the impact of the upper airways is needed. We begin this by comparison of deposition
68 in the airways (from mouth to central airways) in three diverse patients ranging from 11 –
69 49 years old. This can allow simulation of flow created in the upper airways and provide
70 understanding of how this affects deposition throughout the airways, across patients.

71 Results from these simulations are dependent on the inflow conditions, which here is
72 based on the duration and strength of the patient's inhalation. Colasanti et al. (2004) pub-
73 lished breathing profiles of patients who had recently had an exacerbation (around one hour
74 before measurements were taken) show vastly different shape and magnitude from the in-
75 halation waveform which is typically used in respiratory CPFD studies (Inthavong et al.,
76 2010). A sinusoidal inhalation waveform is used by most existing studies (Oakes et al., 2018;
77 Inthavong et al., 2010; Naseri et al., 2017), which mimics a healthy patient's tidal breathing.
78 The variation in flow patterns produced by these differences would therefore give a de-
79 position analysis which may not represent the reliever inhaler's true operating conditions.
80 Different breathing profiles have been utilised (Longest et al., 2012; Khajeh-Hosseini-Dalasm
81 and Longest, 2015), but these were used to represent techniques for different devices (dry-
82 powder compared to metered-dose inhalers), not exacerbating and healthy breathing in a
83 metered-dose inhaler. By applying different inflow conditions, one can understand changes
84 in flow structure during an exacerbation or another desired breathing situation. This knowl-
85 edge would allow manufacturers to tailor inhaled therapeutics to ensure optimal dosage

86 reaches the desired site in the airways, and to provide clinicians and patients the tools with
87 which to maximise inhalation technique during exacerbations.

88 In addition, existing MDI deposition research simplifies particle interactions, which in-
89 cludes treating particle-wall collision as complete sticking. This is a coarse approximation of
90 dissipative lubrication forces between the particle and wall (Legendre et al., 2005; Holbrook
91 and Longest, 2013). To treat as fully sticking therefore neglects rebound and could over-
92 estimate deposition of high inertia particles. Furthermore, MDI studies often exclude van
93 der Waals forces which can cause small particles agglomerate (Hamaker, 1937), and become
94 more inertial. If the increase in inertia is large enough, this can change particle trajectory
95 or chance of rebound, which, in turn would cause early deposition. How these forces alter
96 deposition and compete against each other should be tested. Applying this to simulations
97 made specific to a patient's airway structure under extreme and optimal breathing will fur-
98 ther understanding of drug transport across different health states.

99 Therefore, we aimed to (i) evaluate the need for patient-specific domains in future simu-
100 lations through medical image-based modelling of three diverse patients. To satisfy this we
101 also aimed to (ii) identify the necessary physical effects to produce accurate models of the
102 system (including the mass of drug simulated, van der Waals and particle-wall lubrication
103 forces), and (iii) evaluate variation in deposition during exacerbating breathing.

104 **2. Methods**

105 To answer the research aims above, we evaluated changes in deposition produced by
106 the following variations. Parameters varied included the mass of drug simulated, parti-
107 cle cohesiveness, lubrication forces in particle wall-collisions, and deletion or saving of de-
108 posited particles from the system to mimic absorbing particles with mucus layer. The use
109 of a healthy and exacerbation breathing profile (Colasanti et al., 2004) allowed for analysis
110 of the reliever inhaler during an exacerbation. The effects of patient variation were then
111 analysed using this optimised modelling setup, through comparison under realistic inflow
112 conditions in three patients.

113 *2.1. Medical image processing*

114 Three patients were studied retrospectively using computed tomography (CT) (detailed
115 in Table 1). Use of these retrospective images was approved by Heriot-Watt University (ID:

116 2020-0500-1452). The surface file of the healthy patient’s segmented airways was provided
117 by Dr Filippo Coletti (University of Minnesota). The patients had sufficient variation in age,
118 gender and health status to gather an indication of the benefit of patient-specificity.

Table 1: Information of patients studied in this work. Although a small group, variations in gender, age and disease have been included.

Gender	Age	Illness	Voxel size (mm ³)	Source
Male	47	Healthy	$0.977 \times 0.977 \times 2.5$	Zhang et al. (2012), Banko et al. (2015)
Female	Unknown (adult)	Lung cancer	$0.977 \times 0.977 \times 3.0$	Yang et al. (2017) Yang et al. (2018) Clark et al. (2013)
Male	11	Cystic fibrosis	$0.5254 \times 0.5254 \times 1.0$	

119 Images were processed using 3D Slicer 4.10 (Fedorov et al., 2012). Images were pre-
120 processed by applying isotropic spacing to account for the anisotropic resolution of CT scans
121 (Table 1). For the cancer patient, voxel size was then reduced using a linear interpolation,
122 creating a voxel size of ≈ 0.4 mm to allow extraction of smaller airways. This was also
123 performed on the cystic fibrosis patient. To preserve edges of the airway while blurring
124 lung tissue, an anisotropic diffusion filter was then applied (Duan et al., 2019). Parameters
125 used were conductance 3, 5 iterations and step size of 0.06025. These were based on visual
126 comparison of our segmentations produced from different values of conductance used to
127 good success in medical imaging (Behnaz et al., 2010; Sen et al., 2011).

128 Images were then segmented using a threshold-based region-growing approach to seg-
129 ment areas classified as air without leakage to the background air (Nardelli et al., 2015;
130 Mayer et al., 2004; De Nunzio et al., 2011; Aykac et al., 2003). This semi-automatic process
131 grows the segment from ‘seeds’ which are user declared points within each region, set sep-
132 arately for the airway and surrounding lung tissue. Once each region was grown, labels
133 denoting leaked regions were found by overlaying the segmentation on the scan. Leaked
134 regions were then labelled as airway and the region was grown again until the scan was ob-
135 served to be acceptable quality. This process was applied to the external airways, right and
136 left lungs separately due to variations in the airway image density in each region (Nardelli
137 et al., 2015). This allowed segmentation to a depth ranging from the fourth to sixth bifurca-
138 tion level (G4 – G6, Figure 1).




Figure 1: Segmented airway trees of patients included in the study. The airways are presented from left to right as (a) the healthy, male adult (Banko et al., 2015), (b) the adult, female lung cancer patient (Yang et al., 2017, 2018; Clark et al., 2013), and (c,d) the male child cystic fibrosis patient. The child patient has (c) constricted throat added from the cancer patient (b), and (d) has a dilated throat taken from the healthy patient (a). Areas within the dashed box have been artificially added due to available images not including this region.

139 Some of the upper airways were not included in the CT data, we have found this to be
140 common in most clinical CT scans. To account for this we merged the oral cavity of the
141 healthy patient to the throat of the lung cancer patient. This region was then extracted,
142 scaled and joined to the trachea of the cystic fibrosis patient to complete the missing regions.
143 Scaling was performed such that the intersection of the new and existing regions matched
144 in diameter (resulting in a scaling of 0.8 for the added region). This was later repeated using
145 the throat of healthy patient, after being advised such a narrow, obstructed throat is not
146 characteristic of cystic fibrosis, and likely unique to the cancer patient. The regions which
147 were artificially added are shown graphically in Figure 1 within the dashed box. These
148 excluded regions are of large importance in inhaler simulations as a large portion of the
149 dosage is lost within this part of the airway and the turbulence created here is cascaded
150 through the trachea and main bronchus (Banko et al., 2015).

151 2.2. Mathematical modelling

152 Here we present the mathematical relations used to determine the physical factors in-
153 cluded in our model of the system. We provide the equations governing the fluid and
154 particle solvers in Appendix A. Briefly, particle transport was solved by the discrete el-

155 element method (DEM) using the particle simulator LIGGGHTS (Kloss and Goniva, 2011).
156 This tracks individual particles' trajectories by integrating Newton's equations of motion
157 in time for each particle (Verlet, 1967). Particle collisions were modelled as a linear spring-
158 dashpot system (Cundall and Strack, 1979). Fluid transport through the airways was solved
159 by the volume-filtered mass and momentum continuity equations (Anderson and Jackson,
160 1967; Capecelatro and Desjardins, 2013) implemented in OpenFOAM v2.2 (Weller et al.,
161 1998). Particle and fluid phases were coupled through a version of the CFDEMcoupling
162 platform (Kloss et al., 2012) modified to benefit from faster two-way coupling by Ozel et al.
163 (2016).

164 Filtering the fluid transport equations creates unresolved stresses. In our simulations, we
165 consider stress contributions from the gas pressure gradient ($\nabla \bar{p}_f$) and residual stresses from
166 volume filtering of fluid velocity fluctuations (\mathbf{R}_u) below the cell size, Δ . \mathbf{R}_u is dependent
167 upon the eddy viscosity (μ_t), a term representing turbulence dissipation into the smaller, un-
168 resolved scales. Eddy viscosity is modelled using a dynamic Smagorinsky model (Germano
169 et al., 1991; Lilly, 1992). This models the energy transfer to flow structures smaller than the
170 cell size without a fixed model constant, as this is computed dynamically.

171 We solve particle drag from the relation derived by Beetstra et al. (2007) for monodisperse
172 particles. This drag law is based on the particle's Reynolds number, Re_p , given as

$$Re_p = (1 - \phi) \frac{\rho_f V_{r,i} d_p}{\mu_f}. \quad (1)$$

173 Where $V_{r,i}$ is the relative particle velocity, d_p is the particle diameter, μ_f is the viscosity. As
174 well as determining particle drag, Re_p also characterises particle inertia through the parti-
175 cle's Stokes number,

$$St = (1 - \phi) \frac{\rho_p d_p^2 V_{r,i}}{18 \mu_f D} = \frac{\rho_p}{\rho_f} \frac{d_p}{18 D} Re_p. \quad (2)$$

176 Where D is the airway diameter. Due to their small size, metered-dose inhaler particles
177 have a Stokes number below one, meaning they show high sensitivity to carrier fluid fluc-
178 tuations induced by the complex structure of the upper airways (Kleinstreuer and Zhang,
179 2010). This makes the Stokes number the primary parameter to be adjusted when optimising
180 deposition (Kleinstreuer and Zhang, 2010).

181 Again, due to the particle's small size, particle-particle cohesion from van der Waals
182 forces may influence deposition. Particle attractive energy due to van der Waals force is
183 determined by the material's Hamaker constant, A (Hamaker, 1937). To permit a larger
184 timestep, particles' elastic properties are softened. Therefore the real stiffness (k_R) is re-
185 duced to a soft stiffness (k_S), and the Hamaker constant is amended by the relationship
186 $A^S = A^R(k_S/k_R)^{1/2}$ using the model of Gu et al. (2016a). This reduction of real particle stiff-
187 ness (k_R) to a softer stiffness (k_S) has negligible effect on fluid hydrodynamics and particle
188 cohesion (Gu et al., 2016a; Ozel et al., 2017). To determine A , which is not given in literature
189 for the metered-dose inhaler propellant HFA-134A, we evaluate deposition at three Bond
190 numbers, Bo . Bo is provided by Ozel et al. (2017) as

$$Bo = \frac{F_{vdw}^{\max}}{m_p |\mathbf{g}|} = \frac{A d_p}{24(s_{\min}^R)^2 m_p |\mathbf{g}|}. \quad (3)$$

191 Where F_{vdw}^{\max} is the maximum van der Waals force magnitude occurring when $s = s_{\min}^R$ (the
192 minimum separation distance for a particle at its real stiffness). This was varied three orders
193 of magnitude, $Bo = 10, 100, 1000$ which was sufficient variation to interpret cohesive differ-
194 ences. This magnitude of variation was chosen as it showed changes in deposition without
195 running a large amount of simulations at finer Bo intervals. This also gave A at $Bo = 1000$
196 of the same order of magnitude ($A = 10^{-20}$ J) to drug particles in the inhaler propellant
197 HFA-227 (Engstrom et al., 2009).

198 Further complexities arise when considering particle-wall interactions. This is widely
199 treated as a fully plastic collision due to the presence of a respiratory mucus layer (Miyawaki
200 et al., 2012; Zhang et al., 2018; Chen et al., 2012; Naseri et al., 2017). This may occur due to lu-
201 brication interactions, which have been experimentally shown to damp collision forces (Leg-
202 endre et al., 2005) due to the formation of a thin interfacial film during contact. This relation
203 has been shown to follow the expression

$$e_{iw} = \frac{v_R}{v_C} = \exp\left(-\frac{35}{St_{coll}}\right), \quad (4)$$

204 for solid particles (Legendre et al., 2005). Where subscript R and C are the rebound and pre-
205 collision velocities, respectively, v_T is the terminal velocity of the particle, before it slows

206 due to interaction with the wall and $St_{coll} = (\rho_p + \rho_f)d_p v_T / 9\mu_f$ (Legendre et al., 2006).
207 e follows a sigmoid trend when plotted against St_{coll} , with $St_{coll} < 10$ creating a plastic
208 collision similar to that approximated in modelling of particle-mucus layer interactions. We
209 implemented this relationship to model particle-wall contact force, then when later deleting
210 or freezing deposited particles, use it to determine the cutoff. We use this to model particle-
211 mucus layer collision instead of the typical ‘sticking’ condition (Miyawaki et al., 2012; Zhang
212 et al., 2018; Chen et al., 2012; Naseri et al., 2017). This allows potential for particle rebound
213 after impacting the wall. Therefore, as the particle-wall interaction is better represented,
214 deposition is not over-estimated.

215 2.3. Simulation configuration

216 2.3.1. Single-phase validation

217 We first verified the fluid phase by qualitative comparison to a published experimental
218 study (Banko et al., 2015). The study observed water flow in a 3D printed hollow cast of
219 an adult male patient’s airways (Figure 1a) at a Reynolds number representative of heavy
220 breathing ($Re_{inlet} = \rho_f UD_{inlet} / \mu_f = 3600$ corresponding to $Q = 1$ L/s). Water flow was
221 simulated to first replicate the experiment before advancing to a simulation of airflow to
222 show independence of the fluid simulated when velocity is scaled by its Re . Water was simu-
223 lated using OpenFOAM solver pimpleFoam, then when simulating air we used the CFDEM
224 solver with no particles. We gauged mesh sensitivity by simulating two uniform, hexahedral
225 meshes (5×10^5 and 10^6 cells). As interaction between the gas and particle phases (namely,
226 drag) is dependent on the size of Δ relative to d_p , we made our fine mesh cell size $\Delta = 50d_p$
227 to minimise drag overestimation. This is of the same order of magnitude as coarse-fluid grid
228 simulations performed by Radl and Sundaresan (2014). We kept grid size consistent with
229 our first particle size tested (at $d_p = 10 \mu\text{m}$, $\Delta = 500 \mu\text{m}$) throughout the study to minimise
230 excessive computation time when later reducing particle size.

231 As upstream fluctuations in the experimental apparatus necessitate a turbulent inlet (Sagaut,
232 2006), we implemented a boundary condition which adds random components to the flow.
233 This was used with an inflow velocity of $u_{water} = 0.167$ m/s and $u_{air} = 2.677$ m/s, with a
234 no-slip condition at the wall. Outlets had a uniform, fixed pressure applied to each bronchi.
235 Although not truly representative of outflow conditions within the lung, a uniform outlet
236 condition has been shown to be acceptable when the bronchi are extended a few diame-

237 ters in the axial direction to eliminate secondary flow effects (Zhang et al., 2012). This has
238 been shown to resemble more advanced outlet conditions which consider compliance of the
239 lung (Ma and Lutchen, 2006).

240 2.3.2. Aerosol transport modelling

241 In multiphase simulations we coupled the single-phase approach above to the DEM
242 solver to track monodisperse particles of $d_p = 10$ and $4 \mu\text{m}$. We began with $10 \mu\text{m}$, which are
243 on the upper end of those used in metered-dose inhaler research (Kleinstreuer and Zhang,
244 2010; Watanabe and Watanabe, 2019), to allow faster simulations at this stage to observe
245 variation between patients. This is as timestep size and number of particles (for a desired
246 mass of drug) are dependent upon particle diameter. Particles are classed as deposited and
247 deleted from the system when impacting the wall with low inertia ($St_{coll} < 20$ Legendre
248 et al. (2005)). As CT scan resolution only permitted segmentation to approximately the sixth
249 bifurcation level (Figure 1), particles reaching the end of the bronchial path were classified
250 as reaching the distal airways and deleted. As we this only model a limited amount of bifur-
251 cation levels (between four to six), this is a coarse approximation of downstream behaviour
252 and dosage reaching the small airways.

253 The dosage was released over a period of $t = 0.1$ s (Ju et al., 2010). The particle motion
254 was discretised in time based on calculation of the collision time of the particles, $t_{\text{DEM}} =$
255 $\pi(2k_n/m - \gamma_n^2/4)^{-1/2}/7$ (Gu et al., 2016a). The van der Waals stiffness scaling (Gu et al.,
256 2016a) was set to $A^S = A^R(k_S/k_R)^{1/2} = A^R/31.6$. Particle lubrication force was modelled
257 using mucus layer viscosity ranging from $\mu_{\text{mucus}} = 0.026 - 0.05$ Pa · s dependent on dis-
258 ease (Rubin, 2007) and a density of $\rho_{\text{mucus}} = 1000$ kg/m³ as it is largely made up of water in
259 the upper airways (Olsson et al., 2011). Parameters used are summarised in Table 2. Simu-
260 lations were performed on high-performance computers ROCKS of Heriot-Watt and EDDIE
261 of the University of Edinburgh high-performance computers using 28 – 64 CPU cores.

262 Once the optimal parameters were determined, a time-varying inlet condition was im-
263 plemented to represent a real breathing cycle (Figure 2). For this we used data provided by
264 Colasanti et al. (2004) whom analysed the breathing profile of patients suffering from COPD
265 and cystic fibrosis shortly after an exacerbation. This was also compared to a healthy in-
266 halation profile. To compare the effect of inhalation waveform, the healthy patient was sim-

Table 2: Parameters used in simulations, as well as dimensionless quantities varied. Three separate volume fractions were used to observe sensitivity to the number of dosage simulated. Three Bond numbers were simulated to determine the effect of van der Waals forces. Finally, particle-wall lubrication forces were included by comparing a collision with fixed e and one dependent on St_{coll} .

Parameter	Value	Source
$\rho_g / \text{kg/m}^3$	1.2	Robinson et al. (2007)
$\mu_g / \text{Pa} \cdot \text{s}$	1.8×10^{-5}	
$d_p / \mu\text{m}$	10, 4, 2	Kleinstreuer and Zhang (2010)
$\rho_p / \text{kg/m}^3$	1207	Mexichem (n.d.)
$v_{p,in} / \text{m/s}$	30	Newman (2005)
$k_S / \text{N/m}$	100	Gu et al. (2016a)
k_R / k_S	1000	Chen et al. (2012)
μ_p	0.5	Gu et al. (2019)
e_{ij}	0.9	Gu et al. (2019)
e_{iw}	$0.9, e_{iw}(St_{coll})$	Legendre et al. (2005)
Characteristic Quantities	Value (corresponding physical quantities)	
ϕ_{avg}	$7.4 \times 10^{-8}, 7.4 \times 10^{-7}, 3.7 \times 10^{-6}$ ($N_p = 20 \times 10^3, 200 \times 10^3, 10^6$)	
St	0.5	
Re_p	18.5	
Re_{inlet}	3600	
Bo_p	10, 100, 1000 ($A^R (\text{J}) = 1.5 \times 10^{-22}, 1.5 \times 10^{-21}, 1.5 \times 10^{-20}$)	

267 ulated using both the healthy and exacerbation profile presented by Colasanti et al. (2004).
 268 The two diseased patients were then simulated under the exacerbation inhalation profile. To
 269 evaluate the effect of the missing throat and mouth of the cystic fibrosis patient, we model
 270 this patient using the mouth and throat of the healthy and cancer patient. The magnitude
 271 of the child's inhalation velocity was lowered by half, based on inhalation velocities used
 272 in a similar study (Longest et al., 2006). Following this we focus on the two patients of
 273 main interest, the child cystic fibrosis patient and the healthy adult. We compare the effect
 274 of reducing particle size from $10 \mu\text{m}$ to $4 \mu\text{m}$, and alternating the healthy and exacerbation
 275 breathing profile.

276 2.4. Deposition assessment

277 In all of these cases particle deposition was analysed by regional groupings of the mouth,
 278 throat, trachea, main bronchus and bronchi within each lobe of the lung (as used by Asghar-
 279 ian et al. (2001) and van Holsbeke et al. (2018)). We also provided results grouped into
 280 external airways (mouth to end of first branch), and internal airways (airways within the




Figure 2: Breathing profiles for healthy and diseased patients used in this study (Colasanti et al., 2004). Positive flow rate represents inhalation and negative represents exhalation. A standard sinusoidal breathing profile is shown for comparison. Differences between healthy and simplified breathing conditions are minor, but the exacerbation profile reaches a higher peak inhalation at a faster rate.

281 lungs). We use this to evaluate preferential deposition within airways' different regions.

282 In contrast to the fully plastic particle-wall condition used in literature, our particles may
283 rebound as we resolve collisions over multiple timesteps. We classed particles that had low
284 inertia prior to impacting the wall as deposited. This inertia was based on Equation (4).
285 We compared results where these particles were kept active in the domain to interact with
286 floating particles, or where we simply deleted them. The difference in these was found to
287 be minimal (under 5% in all regions). Therefore we opted to delete them due to superior
288 computational efficiency (reached 0.1 s physical time in 30% faster clock time).

289 Due to the particle's ability to slide along the wall in our parameter study simulations,
290 when stuck it would not be completely stationary. To extract particles on the wall for com-
291 parison to our sticking condition, deposition was defined when the particle velocity was
292 sufficiently below that of the free-stream ($v = 0.01$ m/s, 900 times less than gas velocity
293 in the throat). This velocity cutoff was found through observed comparison of velocities
294 of slowly floating and deposited sliding particles. Particles that were below this threshold
295 were classed as deposited deleted during post-processing.

296 Due to the locally-acting nature of metered-dose inhalers (Lu et al., 2015), it is impor-
297 tant to understand therapeutic distribution and dosage experienced by the patient based on
298 deposition concentration (Solomon et al., 2012). We interpreted this through the dosimetry

299 measure of deposition enhancement factor (DEF) (Balashazy et al., 1999; Longest et al., 2006).
300 We calculate this using the number of particles deposited within a fixed distance (1 mm, area
301 $A_{conc} = \pi (1 \text{ mm})^2$) of the central point of each wall face. This distance was based on that
302 used by Dong et al. (2019). Other studies have used much narrower radii (Longest et al.,
303 2006; Xi et al., 2012), but using this wider radius can account for particle translocation during
304 the time between deposition and absorption. This is made relative to the global deposition
305 by

$$\text{DEF} = \frac{\text{Deposition concentration within } A_{conc} / A_{conc}}{\text{Total deposited particles} / \text{Total airway surface area}}. \quad (5)$$

306 We use this instead of the sum of the deposition efficiencies as the defined areas may over-
307 lap, and this therefore prevents particles being counted multiple times towards the global
308 average.

309 **3. Results**

310 *3.1. Single-phase validation*

311 The sensitivity of aerosol particles to changing flow structures (as $St < 1$) makes single-
312 phase flowfield validation crucial before considering particles. Turbulence induced in the
313 upper airways is the foundation of the flow structure, creating secondary flows which are
314 responsible for deposition in the trachea (Jin et al., 2007; Kleinstreuer and Zhang, 2010).
315 Therefore, the upper airways are a suitable region for the validation (Figure 3). All results
316 have been normalised by the mean velocity in the trachea ($V_{T,\text{water}} = 0.22 \text{ m/s}$ and $V_{T,\text{air}} =$
317 3.51 m/s). The strong jet of flow formed at the throat matches the experimental study well
318 in magnitude and structure, capturing the recirculation zones as the throat expands well.
319 Banko et al. (2015) gave the bulk (area-averaged) velocity U relative to V_T as 1.73 in the
320 glottis, compared to our value of 1.77, producing a 2.3% relative error.

321 The resemblance in flow structure continues in the lower airways, from both coronal and
322 axial views as given in Figure 4 (see Banko et al. (2015) for further comparison). The slight
323 separation seen at the left bronchus (right side of (a)) agrees well with the experimental data.
324 Contours in the axial region (shown in (b)) agree well in shape, accurately capturing recir-
325 culation and asymmetrical flow. However, velocity vectors shown in C-C' and D-D' differ
326 from the published results. This likely stems from differences in time-averaging of such a
327 sensitive parameter in highly unsteady flow. Vectors in B-B' and E-E' match the experimen-




Figure 3: Comparison of single-phase flow in the upper airways to demonstrate mesh independence and independence of water and gas simulations at equal Reynolds numbers. (a) Location of shown contour (red) in domain (Banko et al., 2015, Figure 5), with arrows indicating direction of view for comparison of the normalised velocity magnitude contours of: (b) experimental obtained water flow (Banko et al., 2015, Figure 5), and numerically obtained water flow on a (c) moderate grid density and (d) fine grid. (e) Numerically obtained airflow on a fine grid.




Figure 4: Time-averaged water velocity field at the first bifurcation, structured the same as presented in experimental study (Banko et al., 2015, Figure 9) for ease of comparison. (a) Normalised velocity magnitude at the first bifurcation from the coronal view, and (b) the velocity magnitude normal to the flow at various axial cuts shown in (a).

328 tal data well. Qualitatively comparing numerical and experimental velocity fields (Banko
 329 et al., 2015) verifies that the single-phase flow configuration is suitable to capture the flow
 330 patterns present. To quantitatively validate the solver, we compare the relative bulk velocity
 331 (U/V_T). Banko et al. (2015) gave this as 1.03 in the trachea, matching our solver exactly. In
 332 the left main bronchus, we had a value of 0.67, differing from the experimental results of
 333 0.70 by 4.3%. In the right bronchus the numerical and experimental $U/V_T = 0.88$ and 0.87,
 334 respectively (relative error 1.2%). These relative bulk velocity comparisons at key cross sec-
 335 tions of the airway validate that our solver can reproduce the *in vitro* respiratory velocimetry
 336 measurements of Banko et al. (2015) to an error below 5%.

337 3.2. *Effect of parameter variations*

338 To model inhaler inhalation the simulation's sensitivity to the dosage simulated, van der
339 Waals forces and particle-wall lubrication forces were evaluated. The influence of each of
340 these were examined by their influence on dosage deposition.

341 As physical parameters were varied, one can observe that deposition distinctions are
342 mostly minor, as deposition changes across each lobe were all under 1.5% of the total dosage
343 (Figure 5). When increasing the number of particles the only change came at $N_p = 1,000,000$
344 (Figure 5c), as the throat deposition rose by 2%, in all other regions the difference was less
345 than 1%. For this reason 200,000 particles was chosen for the remaining simulations to
346 reduce run times. Although we have purposely underestimated N_p , the number of parti-
347 cles should not be chosen arbitrarily. Instead the sensitivity of the model to this parameter
348 should be included as an early simulation in all studies where the true payload cannot be
349 simulated. When including particle cohesion and particle-wall lubrication (Figure 5h,i), de-
350 position in the throat due to particle-wall lubrication forces rose by 13% of the total dosage.
351 This effect is reduced by 4% when modelling van der Waals forces, likely explained by the
352 agglomeration of particles providing additional inertia (increasing St_{coll}), thus reducing the
353 energy lost due to lubrication. This also explains why minimal changes are observed in
354 Figure 5(d – f).

355 The parameters taken forward to evaluate deposition variance in the diseased patients
356 were: a dosage of $0.126 \mu\text{g}$ ($N_p = 200,000$ at $d_p = 10 \mu\text{m}$), a Bond number of 1000, and
357 particle-wall lubrication forces. Time-varying breathing profiles were also applied (Fig-
358 ure 2). Although particle count is underestimated, the error is within 5%, for a computation
359 time reduction of 62% ($N_p = 200,000$ took three weeks, whereas $N_p = 1,000,000$ took eight).
360 These parameters were considered to model the particle behaviour accurately, with a small
361 sacrifice made to reduce computational cost.

362 3.3. *Inter-patient variation*

363 Due to the dominance of upper airway deposition, it is difficult to visualise differences
364 in central airway deposition. When viewing deposition as a logarithm the behaviour in the
365 lobes can be analysed with greater ease (Figure 6). Across the five simulations the dosage
366 was mainly deposited in the external airways (Figure 6), deposition here was always greater




Figure 5: Dosage deposited within each region of the airways with time, for the parameter variations given in Table 2. (a, b, c) Compares deposition with simulation of various particle numbers. Remaining rows present results using $N_p = 200,000$. (d, e, f) Shows deposition with variation of the van der Waals force in relation to the dimensionless quantity Bo . (g, h, i) Compares deposition with inclusion of lubrication forces and van der Waals particle-particle interactions. Each line is representative of an airway region, corresponding to the coloured airway included in the left-most plot of each row. An additional grey, dashed line is included to show the rate at which particles enter the system from the inhaler.

367 than half of the payload. Given the size of the particles compared to the distribution used in
 368 inhalers, a large deposit here was expected. For the most constricted external airways (Fig-
 369 ure 6c,d) the deposition fraction was 0.95 and 0.85, respectively. The lower throat deposit
 370 in the child, despite using a scaled replica of the cancer patient's airways above the trachea,
 371 indicating the weaker inhalation is beneficial here. The cystic fibrosis patients' deposition
 372 dropped by 13.4% in the trachea (relative to total dose) when using the dilated airway, how-
 373 ever deposition rises elsewhere meant the total drop was 12.5% (Figure 6d, e). There is an

374 external airway deposition rise of 1.9, 1.7 and 1.5 times when comparing the healthy patient
375 with exacerbation breathing against the cancer and cystic fibrosis patients (constricted and
376 dilated), respectively. Considering only 'stuck' particles (non 'exiting' particles), the ratio of
377 external to internal airway deposition ranged from 3 to 61.

378 Both patients with the constricted throat (Figure 1ii, iii) received below 5% of the dosage
379 to the deep airways (Figure 7). When replacing the constricted throat with the dilated throat
380 in the cystic fibrosis patient, dosage in this region increased to 14% of the total payload.
381 In the two healthy patient simulations this number increased to 31 and 19% for healthy
382 and the exacerbation inhalation. Lobar distribution of these particles for healthy and the
383 exacerbation inhalation was mainly directed to the lower lobes (67 and 56% of total exited)
384 and the left:right lung ratio of dosage reaching the distal airways was 1.1 and 1.6. Left:right
385 deep lung ratio was 0.2 for the lung cancer patient, 0.3 for cystic fibrosis patient (i) and
386 0.91 for cystic fibrosis patient (ii). This shows a noticeable difference between healthy and
387 diseased airways.

388 3.4. Particle size reduction

389 As improvements to device efficiency are generally realised through the patient's breath-
390 ing and the particle sizes, we applied these to the two main cases of interest (the healthy
391 adult and cystic fibrosis child patients). Particle size was reduced to 4 μm using the exacer-
392 bation profile. We applied the healthy breathing profile to both patients with 10 μm particles.
393 Deposition in the external airways gives no clear trend of improvement (Figure 8). We see
394 the change in breathing yields a deposition reduction of 43% for the cystic fibrosis patient,
395 but a rise of 4% in the healthy patient. Similarly reducing the particle size yields a deposition
396 increase of 3% for the cystic fibrosis patient, but a deposition reduction of 56%. This reduc-
397 tion does not appear to impact the dosage reaching the deep lung, as during exacerbating
398 breathing this value does not differ by more than 0.5% for 10 and 4 μm particles.

399 3.5. Dosimetry assessment

400 In all simulations, hotspots were observed at the back of the mouth, throat, upper tra-
401 chea, first and second bifurcations (Figure 9). The healthy patient's drug deposits were
402 limited to this region under normal breathing (Figure 9a,e), but during an exacerbation the
403 particles form a uniform coating across the airways with a DEF value of 1–5 in the bronchi,




Figure 6: Comparison of regional deposited particles in three diseased model airways throughout a breathing cycle (Figure 2). Deposition is shown on a log scale to allow closer analysis of lobar deposits. Again time has been normalised and patient illnesses described each plot. Line colours correspond to region in the coloured, generic airway tree on the left. Rate of particle injection to the domain given by the grey, dashed line. Distribution of exited particles, not considered in this graph, are shown in Figure 7.




Figure 7: Percentage of dosage progressing to the lower airways of each patient, shown for each lobe of the lung. This represents the particles which have ‘exited’ from the patients shown in Figure 6. Overlapping points have been offset to in the x axis to aid visualisation.

404 20 at the first bifurcation, and 20–250 in regions of the throat. This is much larger than under
405 healthy breathing, where the in the throat the range is 10–100, and 10 at the first bifurcation.
406 We see less intense hotspots in bronchi of the two diseased patients. At the first bifurcation,
407 $DEF = 0.2$ and 5 for the cancer and cystic fibrosis patients (i), respectively. The dose is con-
408 centrated in the throat at the narrow throat, where in both patients the values range from 20
409 to 120. Trachea deposition is favoured to the front as the mean DEF here is 1, and 1.6 for the
410 cancer and cystic fibrosis patient, respectively (Figure 9c,d). This is much smaller (the order
411 of 10^{-3}) at the rear of the trachea in these patients (Figure 9g,h). The cystic fibrosis patient
412 with the constricted and dilated throat shows similar local behaviour below the carina, as
413 there are sparse patches of drug deposits. These are narrow and more intense in the cystic
414 fibrosis patient with the dilated throat ($DEF = 1$ to 13 in the first few bifurcations, decreasing
415 to 0.1 to 1.5 in the distal bronchi), but appear the slightly larger in area in the cystic fibrosis
416 patient with the constricted throat. Mean DEF at the first bifurcation is 5.5 (Figure 9e), only
417 0.5 higher than the same patient with the constricted upper trachea (Figure 9d).

418 4. Discussion

419 In this study we aimed to evaluate deposition in patient-specific models during exacer-
420 bating breathing, compared to during healthy breathing. This allowed the investigation to




Figure 8: Delivery changes in (a) external (mouth to first bifurcation) and (b) deep airways in two cases of main interest as inhaler particle size and breathing profile change. Line style is consistent with all variations in the patient. Black, blue and red lines denote exacerbating breathing with 10 μm , healthy breathing with the same particle size, and exacerbating breathing with 4 μm particles.

421 consider short-acting bronchodilators ('reliever' inhalers). By investigating this in a small,
 422 diverse patient group we found patient-specific domains to be a necessity in future studies.
 423 Results showed less drug reaching the deep lung during an exacerbation, but the main dif-
 424 ferences came in the patients with distinct changes in upper airways (shape and size). The
 425 increased upper airway deposition is attributed to the greater constriction and complexity
 426 here, particularly in the cancer patient (Figure 1b). From the brief parameter study, this ap-
 427 peared to overrule the effect of particle-particle interactions such as collisions. This shows
 428 that patient-specificity in the upper airways is crucial for accurate deposition prediction.




Figure 9: Concentration of drug deposits in each model, normalised by total global deposition (DEF, Equation (5)). Hotspots visualised from the (a-e) front and (f-j) rear of each model. The maximum value (DEF = 350), describes an area with a drug concentration 350 times greater than the mean DEF of 1. Dosage is most concentrated in the throat as shown in Figure 6.

429 We have seen unexpected reactions from some patients to reducing particle size and
430 applying the healthy breathing profile (Figure 8). Typically smaller particles and steadier
431 breathing reduce mouth and throat deposition as shown *in vivo* by Usmani et al. (2005).
432 This further emphasises the need for the use of patient-specific domains, as we have seen
433 a small rise in external airway deposition when reducing particle size from 10 to 4 μm for
434 the cystic fibrosis patient. Conversely, for the healthy patient we see a external airway de-

435 position rise of over double with this change in particle sizes. This agrees with reduced
436 deposition in central airways for smaller particles (Usmani et al., 2005). Similar trends were
437 seen when comparing breathing profiles in the healthy patient, as there was a small rise in
438 external airway deposition with the healthier breathing profile (but also a rise in deep lung
439 dosage). A potential cause for these abnormal observations could be the unpredictability
440 of the mesoscale interactions such as particle collisions, van der Waals forces and particle-
441 wall lubrication, and their change with the changing flow structures in different patient
442 airways (Figure 5). In contrast to other patient-specific deposition studies that did not con-
443 sider particle-particle interactions (Choi et al., 2018; Koullapis et al., 2018; Poorbahrami and
444 Oakes, 2019), we chose to use CFD-DEM with particle-particle interactions. This was as
445 cohesive van der Waals forces have been known to influence the transport of micro-scale
446 particles (Gu et al., 2016a). Soft-sphere (treating particles as deformable) deposition studies
447 have been implemented before but only to observe dynamics in simplified airways (Chen
448 et al., 2012; Wang et al., 2017). This allows understanding of particle dynamics in a fixed
449 system. However, our results in Figure 6 have shown, there are changes in flow dynamics
450 across different patients which may alter the influence of particle interactions. For example,
451 in narrow airways the particle concentration will be denser than in a patient with wider
452 airways and cause more cohesion. This is a speculative explanation as our results in Fig-
453 ure 5 show small variation with cohesive forces. The minor influence of cohesion in our
454 simulations is aligned with the small localised changes shown by Wang et al. (2017) when
455 modelling cohesion. As suggested by Islam et al. (2020) the effect of particle-particle interac-
456 tions should be investigated across many cases to understand their influence on respiratory
457 drug delivery, but our study has provided a first step towards this. To use modelling to in-
458 form patient treatments an understanding of different particle forces and their change with
459 drug properties is important.

460 Dosimetry analysis across the patients show noticeable differences in deposition in the
461 trachea (Figure 9), attributable to transitioning from the fast-flowing, constricted throat to
462 the expanding and curved trachea, of the cystic fibrosis and cancer patients. This agrees with
463 single-phase simulations of Wei et al. (2017) that found flow to vary with orientation, as well
464 as Bates et al. (2016) who showed the effect of pathological trachea curvature on gas pressure

465 and energy loss. Also the change in relative orientation of the trachea to gravity present an
466 additional factor to deposition changes. We also see a more uniform coating in the central
467 airways of the healthy patient during exacerbating breathing, compared to normal breath-
468 ing. As drug concentration across the airway surface is important in its dissolution into the
469 tissue (Solomon et al., 2012), this provides a deeper understanding of the drug's absorption
470 than a simple deposition analysis. These results could be input to a model of the particle's
471 interaction with the tissue at smaller scales, as has been done by Olsson and Bäckman (2018)
472 using 1D deposition data. Using CPFDD for this could further inform clinicians in comparing
473 potential treatment and delivery techniques for a patient.

474 When observing intra-patient drug delivery, the results presented show an uneven dis-
475 tribution across the lobes. There is a clear favour in transport to the lower lobes of the lung
476 (Figure 7). This is similar to observations made by Lambert et al. (2011). Deposition is dom-
477 inant in the right lung in the diseased patients, agreeing with experimental data (Usmani
478 et al., 2005; De Backer et al., 2008). Patient-specific models could be used to attain a bal-
479 anced dosage distribution, or target a specific region. This could allow for improved symp-
480 tom relief through inhaler design informed by knowledge of regions sensitive to local in-
481 flammation (Barbu et al., 2011), allowing for more efficient devices. Additionally, cancerous
482 regions of the lung could be targetted for chemotherapy using nebulisers (Tatsumura et al.,
483 1993; Kleinstreuer and Zhang, 2003; Kleinstreuer et al., 2007). Clinicians could therefore pre-
484 dict and tailor the chemotherapeutic agent delivery through patient-specific CPFDD models
485 to minimise radiation reaching undesired areas of the lung. As course of chemotherapeu-
486 tic treatment is given over a large period of time (given in three week intervals by Wittgen
487 et al. (2007)), this fits well with a high accuracy, time-consuming modelling method such as
488 CFD-DEM.

489 Interestingly, the only lobar distribution changes in deep lung delivery occurred in the
490 healthy patient as the left upper lobe received less medication with healthier breathing (Fig-
491 ure 7). Apart from this, the quantity of the dosage reaching distal lung regions increased
492 with the longer, slower inhalation, but the distribution among lobes remained similar. This
493 was also true for the cystic fibrosis patient (Figure 8b). This finding is beneficial as it sug-
494 gests the drug's behaviour does not differ significantly in extreme circumstances. However

495 this is limited by a lack of knowledge of ventilation changes during exacerbations. Such
496 information can be obtained by imaging combined with respiratory tests during healthy
497 conditions (De Backer et al., 2010, 2014). To model deposition during an exacerbation, pa-
498 rameters usually obtained from imaging may need to be approximated in future studies.
499 However, CPFD can be used to model exacerbations and avoid any dangerous experiments.

500 Limitations of this study included the absence of imaging data available for the throat
501 and mouth of the child, meaning this region was taken from the other patients and scaled.
502 This of course limits the specificity of the main deposition site. However by simulating with
503 the two available throat geometries merged to the child's trachea we can see that the deposi-
504 tion in this region itself is unaffected (only changing 1%). The only differences are observed
505 downstream in trachea deposition (Figure 6) and deep lung dosage (Figure 7). Therefore, to
506 neglect this region completely would harm the accuracy of the results downstream as flow
507 generated in the upper airways heavily impacts downstream behaviour of both the gas and
508 the particles (Figure 4). However, adding this region from adult patient to a child does take
509 into account the maturational effects of adolescence on the airway, which may impact depo-
510 sition here. In future studies, images containing the mouth and throat are needed to ensure
511 this important section is patient-specific.

512 An additional limitation is that patients lying down in scans may have slightly different
513 airway shape and orientation when standing or sitting upright (Jan et al., 1994), as is a typical
514 posture when taking inhalers. If using image-based CPFD to recommend treatments, the
515 patient images should be consistent with their typical posture when using their treatment
516 where possible.

517 Only modelling the small number of airway bifurcation levels visible in the CT scan lim-
518 its the model to only providing deposition information about the upper and central airways.
519 To understand drug delivery in the smaller more distal airways the particles 'exiting' from
520 our model's outlets could be coupled to analytical 1D models (Koullapis et al., 2019). These
521 models predict deposition based on particle size, estimated airway length and diameter,
522 and flow rate. This would allow for a coarse prediction of drug delivery and efficacy in the
523 targeted small airways.

524 Assumptions included the simulation of a uniform particle distribution. A uniform dis-

525 tribution is commonly used to research aerosol physics experimentally (Usmani et al., 2005,
526 2003), although does not directly represent the varying size distribution of inhaler parti-
527 cles (Dolovich, 1991). This is due to the small range of particle sizes (geometric standard
528 deviation below two (Mitchell et al., 2003)) in a real device, meaning $St < 1$ in all cases,
529 therefore the particles will exhibit high sensitivity to flow changes in both polydisperse and
530 monodisperse flows. Deposition results should not be appreciably different as no transport
531 characteristics are changed by this approximation. This allowed patient morphology differ-
532 ences to be evaluated in a simpler manner, without sacrificing accuracy.

533 A final modelling limitation is the softening of the particles. Particle softening is stan-
534 dard in DEM simulations to permit a larger DEM timestep as the particle's collision happens
535 over a longer period due to a lower stiffness. We mitigate an impact of increased van der
536 Waals forces by including the cohesion model of Gu et al. (2016a). This model makes co-
537 hesive particle flows independent of their stiffness, and therefore increases our simulation
538 timestep from $t_{\text{DEM}} = 0.8 \text{ ns}$ to 25 ns. This reduction of real particle stiffness (k_R) to a softer
539 stiffness (k_S) has been shown to have negligible effect on fluid hydrodynamics and particle
540 cohesion (Gu et al., 2016a; Ozel et al., 2017). The use of this model therefore makes the effect
541 of softening particles negligible. This allows us to use DEM to model inhaler particle-particle
542 and particle-wall interactions with feasible computation times.

543 5. Conclusion

544 We have performed patient-specific inhaler deposition simulations across three diverse
545 patients during exacerbating inhalation conditions. This has been compared to a healthy
546 control patient and using a healthy and exacerbating breathing profile, showing that during
547 an exacerbation less of the drug reaches the deep lung.

548 We have applied common means of improving drug delivery such as reduced particle
549 size and a slower, steadier inhalation. Neither of these showed a common reduction in ex-
550 ternal airway deposition. This also shows the shortcomings in treating diverse populations
551 with generic treatments. This demonstrates the need for personalised airways in respiratory
552 CPFD studies, including the mouth and throat.

553 In the healthy patient the distribution of particles behaves as expected. This was fairly
554 balanced across each lung, and primarily in the lower lobes of the lung (due to particle
555 inertia). However we found particle distribution to be far less balanced in the diseased

556 patients, as left to right lung deposition ratio was as low as 0.2 in their worst case. We
557 predict this heterogeneity may be furthered upon inclusion of ventilation differences in the
558 study to follow—particularly if patients studied suffer from issues such as mucus plugging
559 or collapsed lung regions.

560 **Acknowledgements**

561 For their early involvement and insight into the issue faced by patients, the authors
562 would like to thank Elisabeth Ehrlich and Olivia Fulton. Also Carol Porteous (Patient Public
563 Involvement Advisor) who arranged our contact.

564 The authors thank Prof. Vicki Stone from Heriot-Watt University for fruitful discussions.
565 The authors also thank Dr Filippo Coletti from University of Minnesota for providing the
566 surface file of the healthy patient’s segmented airways that enabled our model validation
567 and was used to compare deposition across the patients. AO thanks Prof. Sankaran Sun-
568 daresan from Princeton University for his support and fruitful discussions. JW thanks Dr
569 Rudolf Hellmuth from Vascular Flow Technologies for fruitful discussions.

570 JW was funded by an Institution of Mechanical Engineers Postgraduate Masters Schol-
571 arship 2018, a Scottish Funding Council Masters fee scholarship 2018, and a Carnegie-Trust
572 for the Universities of Scotland PhD scholarship 2019.

573 **Appendix A. Gas and solid-phase modelling**

574 Simulations in this study solve fluid transport through the respiratory system on a Eu-
575 lerian grid with Lagrangian particle tracking using the discrete element method (DEM).
576 We solve the volume filtered mass (A.1) and momentum (A.2) continuity equations at each
577 finite-volume cell. Here they are presented in terms of the volume filtered variables, ac-
578 counting for particle interactions as derived by Anderson and Jackson (1967) and Capecela-
579 tro and Desjardins (2013), with overbars denoting filtered terms and bold, lower- and upper-
580 case characters describing vectors and second order tensors, respectively,

$$\frac{\partial}{\partial t}(1 - \phi) + \nabla \cdot [(1 - \phi)\bar{\mathbf{u}}] = 0, \quad (\text{A.1})$$

$$\rho_f(1 - \phi) \left(\frac{\partial \bar{\mathbf{u}}}{\partial t} + \bar{\mathbf{u}} \cdot \nabla \bar{\mathbf{u}} \right) = \nabla \cdot (\bar{\boldsymbol{\tau}} - \mathbf{R}_u) + \Phi_d + \rho_f(1 - \phi)\mathbf{g}. \quad (\text{A.2})$$

581 Where subscript t is time, $\bar{\mathbf{u}}$ is the filtered local velocity vector, \bar{p} is the filtered local fluid-
 582 pressure, ρ_f is the fluid density, ϕ is the particle volume fraction, \mathbf{g} is gravity (assumed con-
 583 stantly acting downwards at 9.81 N/kg), the force caused by interaction with the discrete
 584 phase is $-\Phi_d$, \mathbf{R}_μ is the sub-grid stress from filtering, modelled using a dynamic Smagorin-
 585 sky model (described in Section 2.2). $\bar{\boldsymbol{\tau}}$ is the filtered fluid stress tensor, composed of the
 586 fluid pressure gradient ($\nabla\bar{p}$), the deviatoric viscous stress tensor (labelled below), and an
 587 additional term arising from filtering of sub-grid velocity fluctuations (\mathbf{R}_μ) (Capecelatro and
 588 Desjardins, 2013)

$$\bar{\boldsymbol{\tau}} = \nabla\bar{p} + \underbrace{\mu_f \left[\nabla\bar{\mathbf{u}} + \nabla\bar{\mathbf{u}}^T - \frac{2}{3}(\nabla \cdot \bar{\mathbf{u}})\mathbf{I} \right]}_{\text{deviatoric viscous stress tensor}} + \mathbf{R}_\mu \quad (\text{A.3})$$

589 Where \mathbf{I} is an identity tensor and \mathbf{R}_μ is the term arising from filtering velocity gradients. In
 590 this study we dismissed \mathbf{R}_μ to be included in a later study, and the deviatoric part of the
 591 stress tensor due to its minor influence on gas-solid flows in comparison to \mathbf{R}_μ (Agrawal
 592 et al., 2001). Φ_d is dependent on the interaction force between particles and fluid ($f_{f \rightarrow p,i}$) of
 593 all particles within a cell volume ($\mathcal{V}_{\text{cell}}$) by, $\Phi_d = -\frac{\sum_i^{N_p} f_{f \rightarrow p,i}}{\mathcal{V}_{\text{cell}}}$ (Anderson and Jackson, 1967;
 594 Capecelatro and Desjardins, 2013; Ozel et al., 2017). For a particle i , this is related to the
 595 filtered fluid stresses and the particle's drag by $f_{f \rightarrow p,i} = \mathcal{V}_i \nabla \cdot \bar{\boldsymbol{\tau}} + f_{d,i}$, where $f_{d,i}$ is the drag
 596 force, taken from Beetstra et al. (2007).

597 Newton's equations of motion are used to track particle linear motion (A.4) and angular
 598 motion (A.5) (Cundall and Strack, 1979; Capecelatro and Desjardins, 2013), by

$$m_i \frac{d\mathbf{v}_i}{dt} = \sum_j (f_{c,ij}^n + f_{c,ij}^t) + \sum_w (f_{c,iw}^n + f_{c,iw}^t) + \sum_k f_{v,ik} + f_{f \rightarrow p,i} + m_i \mathbf{g} \quad (\text{A.4})$$

$$I_i \frac{d\boldsymbol{\omega}_i}{dt} = \sum_j (\mathbf{n} \times f_{c,ij}^t). \quad (\text{A.5})$$

599 Where m_i is the mass of a particle, i , v and ω are the particle's translational and angular
 600 velocity, respectively, f_c is the contact force from a particle-particle collision (subscript ij),
 601 and particle-wall collision (subscript iw), in the normal and tangential directions shown by
 602 sub or superscript n and t , respectively. van der Waals forces are shown with v . Angular
 603 momentum (A.5) from inter-particle collisions depends on outward unit normal vector from
 604 particle centre to the point of collision, \mathbf{n} , and the tangential contact force $f_{c,ij}^t$. Particle

605 contact forces are solved here using a linear spring-dashpot model (Cundall and Strack,
606 1979; Capecelatro and Desjardins, 2013),

$$\mathbf{f}_{c,ij}^n = k_n + \delta_n \mathbf{n}_{ij} - \gamma_n m^* \mathbf{v}_{ij}^n, \quad (\text{A.6})$$

$$\mathbf{f}_{c,ij}^t = \begin{cases} k_t \mathbf{t}_{ij} - \gamma_t m^* \mathbf{v}_{ij}^t & \text{for } |\mathbf{f}_{c,ij}^t| < \mu_s |\mathbf{f}_{c,ij}^n|, \\ -\mu_s |\mathbf{f}_{c,ij}^n| \frac{\mathbf{t}_{ij}}{|\mathbf{t}_{ij}|} & \text{for } |\mathbf{f}_{c,ij}^t| \geq \mu_s |\mathbf{f}_{c,ij}^n|. \end{cases} \quad (\text{A.7})$$

607 Where k , is the particle's spring constant with $k_t = 2k_n/7$ (Matuttis et al., 2000), δ is the
608 particle overlap distance, γ is the viscous damping coefficient. γ_n is calculated from the
609 coefficient of restitution $e = \exp(\gamma_n \pi / \sqrt{4k_n/m^* - \gamma_n^2})$ (Gu et al., 2016b). $\gamma_t = 2\gamma_n/7$. Effec-
610 tive particle mass is $m^* = m_i m_j / (m_i + m_j)$, in particle-wall collisions $m^* = m_i$, as one radius
611 is assumed infinite (Gu et al., 2016a); μ_s is the sliding coefficient; \mathbf{t}_{ij} represents the tangential
612 displacement due to a collision, found from the integral of its velocity component.

613 References

- 614 Agrawal, K., Loezos, P. N., Syamlal, M. and Sundaresan, S. (2001), 'The role of meso-scale
615 structures in rapid gas–solid flows', *Journal of Fluid Mechanics* **445**, 151–185.
- 616 Anderson, T. B. and Jackson, R. (1967), 'Fluid mechanical description of fluidized beds. equa-
617 tions of motion', *Industrial & Engineering Chemistry Fundamentals* **6**(4), 527–539.
- 618 Anjilvel, S. and Asgharian, B. (1995), 'A multiple-path model of particle deposition in the rat
619 lung', *Fundamental and Applied Toxicology* **28**(1), 41–50.
- 620 Asgharian, B., Hofmann, W. and Bergmann, R. (2001), 'Particle deposition in a multiple-path
621 model of the human lung', *Aerosol Science & Technology* **34**(4), 332–339.
- 622 Aykac, D., Hoffman, E. A., McLennan, G. and Reinhardt, J. M. (2003), 'Segmentation and
623 analysis of the human airway tree from three-dimensional X-ray CT images', *IEEE trans-
624 actions on medical imaging* **22**(8), 940–950.
- 625 Balashazy, I., Hofmann, W. and Heistracher, T. (1999), 'Computation of local enhancement
626 factors for the quantification of particle deposition patterns in airway bifurcations', *Journal
627 of Aerosol Science* **30**(2), 185–203.

- 628 Banko, A., Coletti, F., Schiavazzi, D., Elkins, C. and Eaton, J. (2015), 'Three-dimensional
629 inspiratory flow in the upper and central human airways', *Experiments in Fluids* **56**(6), 117.
- 630 Barbu, C., Iordache, M. and Man, M. (2011), 'Inflammation in COPD: pathogenesis, local
631 and systemic effects', *Rom J Morphol Embryol* **52**(1), 21–27.
- 632 Bates, A., Cetto, R., Doorly, D., Schroter, R., Tolley, N. and Comerford, A. (2016), 'The ef-
633 fects of curvature and constriction on airflow and energy loss in pathological tracheas',
634 *Respiratory physiology & neurobiology* **234**, 69–78.
- 635 Beetstra, R., van der Hoef, M. A. and Kuipers, J. (2007), 'Drag force of intermediate reynolds
636 number flow past mono-and bidisperse arrays of spheres', *AIChE journal* **53**(2), 489–501.
- 637 Behnaz, A. S., Snider, J., Chibuzor, E., Esposito, G., Wilson, E., Yaniv, Z., Cohen, E. and
638 Cleary, K. (2010), Quantitative ct for volumetric analysis of medical images: initial results
639 for liver tumors, in 'Medical Imaging 2010: Image Processing', Vol. 7623, International
640 Society for Optics and Photonics, p. 76233U.
- 641 Borghardt, J. M., Weber, B., Staab, A. and Kloft, C. (2015), 'Pharmacometric models for char-
642 acterizing the pharmacokinetics of orally inhaled drugs', *The AAPS journal* **17**(4), 853–870.
- 643 Capecelatro, J. and Desjardins, O. (2013), 'An euler–lagrange strategy for simulating particle-
644 laden flows', *Journal of Computational Physics* **238**, 1–31.
- 645 Chen, X., Zhong, W., Zhou, X., Jin, B. and Sun, B. (2012), 'CFD–DEM simulation of particle
646 transport and deposition in pulmonary airway', *Powder Technology* **228**, 309–318.
- 647 Choi, S., Miyawaki, S. and Lin, C.-L. (2018), 'A feasible computational fluid dynamics study
648 for relationships of structural and functional alterations with particle depositions in severe
649 asthmatic lungs', *Computational and mathematical methods in medicine* **2018**.
- 650 Clark, A. (1995), 'Medical aerosol inhalers: past, present, and future', *Aerosol science and*
651 *technology* **22**(4), 374–391.
- 652 Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S.,
653 Maffitt, D., Pringle, M. et al. (2013), 'The Cancer Imaging Archive (TCIA): maintaining
654 and operating a public information repository', *Journal of digital imaging* **26**(6), 1045–1057.

- 655 Colasanti, R. L., Morris, M. J., Madgwick, R. G., Sutton, L. and Williams, E. M. (2004), 'Anal-
656 ysis of tidal breathing profiles in cystic fibrosis and COPD', *Chest* **125**(3), 901–908.
- 657 Cundall, P. A. and Strack, O. D. (1979), 'A discrete numerical model for granular assemblies',
658 *Geotechnique* **29**(1), 47–65.
- 659 Darquenne, C., Fleming, J. S., Katz, I., Martin, A. R., Schroeter, J., Usmani, O. S., Venegas, J.
660 and Schmid, O. (2016), 'Bridging the gap between science and clinical efficacy: physiology,
661 imaging, and modeling of aerosols in the lung', *Journal of aerosol medicine and pulmonary*
662 *drug delivery* **29**(2), 107–126.
- 663 Das, P., Nof, E., Amirav, I., Kassinos, S. C. and Sznitman, J. (2018), 'Targeting inhaled aerosol
664 delivery to upper airways in children: Insight from computational fluid dynamics (cfd)',
665 *PloS one* **13**(11), e0207711.
- 666 De Backer, J., Vos, W., Gorlé, C., Germonpré, P., Partoens, B., Wuyts, F., Parizel, P. M. and
667 De Backer, W. (2008), 'Flow analyses in the lower airways: patient-specific model and
668 boundary conditions', *Medical engineering & physics* **30**(7), 872–879.
- 669 De Backer, J., Vos, W., Vinchurkar, S., Van Holsbeke, C., Poli, G., Claes, R., Salgado, R. and
670 De Backer, W. (2014), 'The effects of extrafine beclometasone/formoterol (bdp/f) on lung
671 function, dyspnea, hyperinflation, and airway geometry in copd patients: novel insight
672 using functional respiratory imaging', *Journal of aerosol medicine and pulmonary drug delivery*
673 **27**(0), 1–12.
- 674 De Backer, J. W., Vos, W. G., Vinchurkar, S. C., Claes, R., Drollmann, A., Wulfrank, D., Parizel,
675 P. M., Germonpré, P. and De Backer, W. (2010), 'Validation of computational fluid dynam-
676 ics in ct-based airway models with spect/ct', *Radiology* **257**(3), 854–862.
- 677 De Nunzio, G., Tommasi, E., Agrusti, A., Cataldo, R., De Mitri, I., Favetta, M., Maglio, S.,
678 Massafra, A., Quarta, M., Torsello, M. et al. (2011), 'Automatic lung segmentation in CT
679 images with accurate handling of the hilar region', *Journal of digital imaging* **24**(1), 11–27.
- 680 Dockrell, M., Partridge, M. and Valovirta, E. (2007), 'The limitations of severe asthma: the
681 results of a european survey', *Allergy* **62**(2), 134–141.

- 682 Dolovich, M. (1991), 'Measurement of particle size characteristics of metered dose inhaler
683 (MDI) aerosols', *Journal of Aerosol Medicine* **4**(3), 251–263.
- 684 Dong, J., Tian, L. and Ahmadi, G. (2019), 'Numerical assessment of respiratory airway ex-
685 posure risks to diesel exhaust particles', *Experimental and Computational Multiphase Flow*
686 **1**(1), 51–59.
- 687 Duan, H.-H., Su, G.-Q., Huang, Y.-C., Song, L.-T. and Nie, S.-D. (2019), 'Segmentation of pul-
688 monary vascular tree by incorporating vessel enhancement filter and variational region-
689 growing', *Journal of X-ray science and technology* **27**(2), 343–360.
- 690 Elborn, J. S. (2016), 'Cystic fibrosis', *The lancet* **388**(10059), 2519–2531.
- 691 Engstrom, J. D., Tam, J. M., Miller, M. A., Williams, R. O. and Johnston, K. P. (2009), 'Tem-
692 plated open floccs of nanorods for enhanced pulmonary delivery with pressurized metered
693 dose inhalers', *Pharmaceutical research* **26**(1), 101–117.
- 694 Fedorov, A., Beichel, R., Kalpathy-Cramer, J., Finet, J., Fillion-Robin, J.-C., Pujol, S., Bauer,
695 C., Jennings, D., Fennessy, F., Sonka, M. et al. (2012), '3d slicer as an image computing
696 platform for the quantitative imaging network', *Magnetic resonance imaging* **30**(9), 1323–
697 1341.
- 698 Germano, M., Piomelli, U., Moin, P. and Cabot, W. H. (1991), 'A dynamic subgrid-scale eddy
699 viscosity model', *Physics of Fluids A: Fluid Dynamics* **3**(7), 1760–1765.
- 700 Gruffydd-Jones, K., Thomas, M., Roman-Rodríguez, M., Infantino, A., FitzGerald, J. M., Pa-
701 vord, I., Haddon, J. M., Elsasser, U. and Vogelberg, C. (2019), 'Asthma impacts on work-
702 place productivity in employed patients who are symptomatic despite background ther-
703 apy: a multinational survey', *Journal of asthma and allergy* **12**, 183.
- 704 Gu, Y., Ozel, A., Kolehmainen, J. and Sundaresan, S. (2019), 'Computationally generated
705 constitutive models for particle phase rheology in gas-fluidized suspensions', *Journal of*
706 *Fluid Mechanics* **860**, 318–349.
- 707 Gu, Y., Ozel, A. and Sundaresan, S. (2016a), 'A modified cohesion model for CFD–DEM
708 simulations of fluidization', *Powder technology* **296**, 17–28.

- 709 Gu, Y., Ozel, A. and Sundaresan, S. (2016b), 'Rheology of granular materials with size distri-
710 butions across dense-flow regimes', *Powder technology* **295**, 322–329.
- 711 Hamaker, H. (1937), 'The london—van der waals attraction between spherical particles',
712 *physica* **4**(10), 1058–1072.
- 713 Holbrook, L. T. and Longest, P. W. (2013), 'Validating cfd predictions of highly localized
714 aerosol deposition in airway models: In vitro data and effects of surface properties', *Jour-
715 nal of Aerosol Science* **59**, 6–21.
- 716 Inthavong, K., Choi, L.-T., Tu, J., Ding, S. and Thien, F. (2010), 'Micron particle deposition in a
717 tracheobronchial airway model under different breathing conditions', *Medical engineering
718 & physics* **32**(10), 1198–1212.
- 719 Islam, M. S., Paul, G., Ong, H. X., Young, P. M., Gu, Y. and Saha, S. C. (2020), 'A review
720 of respiratory anatomical development, air flow characterization and particle deposition',
721 *International Journal of Environmental Research and Public Health* **17**(2), 380.
- 722 Jan, M. A., Marshall, I. and Douglas, N. J. (1994), 'Effect of posture on upper airway di-
723 mensions in normal human.', *American Journal of Respiratory and Critical Care Medicine*
724 **149**(1), 145–148.
- 725 Jin, H., Fan, J., Zeng, M. and Cen, K. (2007), 'Large eddy simulation of inhaled particle
726 deposition within the human upper respiratory tract', *Journal of Aerosol Science* **38**(3), 257–
727 268.
- 728 Ju, D., Shrimpton, J. and Hearn, A. (2010), 'The effect of reduction of propellant mass frac-
729 tion on the injection profile of metered dose inhalers', *International journal of pharmaceutics*
730 **391**(1-2), 221–229.
- 731 Katsaounou, P., Odemyr, M., Spranger, O., Hyland, M. E., Kroegel, C., Conde, L. G., Gore, R.,
732 Menzella, F., Ribas, C. D., Morais-Almeida, M. et al. (2018), 'Still fighting for breath: a pa-
733 tient survey of the challenges and impact of severe asthma', *ERJ open research* **4**(4), 00076–
734 2018.

- 735 Khajeh-Hosseini-Dalasm, N. and Longest, P. W. (2015), 'Deposition of particles in the alve-
736 olar airways: inhalation and breath-hold with pharmaceutical aerosols', *Journal of aerosol*
737 *science* **79**, 15–30.
- 738 Kleinstreuer, C., Shi, H. and Zhang, Z. (2007), 'Computational analyses of a pressurized
739 metered dose inhaler and a new drug-aerosol targeting methodology', *Journal of Aerosol*
740 *Medicine* **20**(3), 294–309. PMID: 17894536.
741 **URL:** <https://doi.org/10.1089/jam.2006.0617>
- 742 Kleinstreuer, C. and Zhang, Z. (2003), 'Targeted drug aerosol deposition analysis for a four-
743 generation lung airway model with hemispherical tumors', *Transactions-American Society*
744 *of Mechanical Engineers Journal of Biomechanical Engineering* **125**(2), 197–206.
- 745 Kleinstreuer, C. and Zhang, Z. (2010), 'Airflow and particle transport in the human respira-
746 tory system', *Annual review of fluid mechanics* **42**, 301–334.
- 747 Kloss, C. and Goniva, C. (2011), 'LIGGGHTS–open source discrete element simulations of
748 granular materials based on LAMMPS', *Supplemental Proceedings: Materials Fabrication,*
749 *Properties, Characterization, and Modeling* **2**, 781–788.
- 750 Kloss, C., Goniva, C., Hager, A., Amberger, S. and Pirker, S. (2012), 'Models, algorithms and
751 validation for opensource DEM and CFD–DEM', *Progress in Computational Fluid Dynamics,*
752 *an International Journal* **12**(2-3), 140–152.
- 753 Koullapis, P., Kassinos, S. C., Muela, J., Perez-Segarra, C., Rigola, J., Lehmkuhl, O., Cui,
754 Y., Sommerfeld, M., Elcner, J., Jicha, M. et al. (2018), 'Regional aerosol deposition in the
755 human airways: The siminhale benchmark case and a critical assessment of in silico meth-
756 ods', *European Journal of Pharmaceutical Sciences* **113**, 77–94.
- 757 Koullapis, P., Ollson, B., Kassinos, S. C. and Sznitman, J. (2019), 'Multiscale in silico lung
758 modeling strategies for aerosol inhalation therapy and drug delivery', *Current Opinion in*
759 *Biomedical Engineering* .
- 760 Lambert, A. R., O'shaughnessy, P. T., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2011),
761 'Regional deposition of particles in an image-based airway model: large-eddy simulation
762 and left-right lung ventilation asymmetry', *Aerosol Science and Technology* **45**(1), 11–25.

- 763 Legendre, D., Daniel, C. and Guiraud, P. (2005), 'Experimental study of a drop bouncing on
764 a wall in a liquid', *Physics of Fluids* **17**(9), 097105.
- 765 Legendre, D., Zenit, R., Daniel, C. and Guiraud, P. (2006), 'A note on the modelling of the
766 bouncing of spherical drops or solid spheres on a wall in viscous fluid', *Chemical engineer-
767 ing science* **61**(11), 3543–3549.
- 768 Lilly, D. K. (1992), 'A proposed modification of the germano subgrid-scale closure method',
769 *Physics of Fluids A: Fluid Dynamics* **4**(3), 633–635.
- 770 Longest, P. W., Hindle, M., Choudhuri, S. D. and Xi, J. (2008), 'Comparison of ambient and
771 spray aerosol deposition in a standard induction port and more realistic mouth–throat
772 geometry', *Journal of Aerosol Science* **39**(7), 572–591.
- 773 Longest, P. W., Tian, G., Walenga, R. L. and Hindle, M. (2012), 'Comparing mdi and dpi
774 aerosol deposition using in vitro experiments and a new stochastic individual path (sip)
775 model of the conducting airways', *Pharmaceutical research* **29**(6), 1670–1688.
- 776 Longest, P. W., Vinchurkar, S. and Martonen, T. (2006), 'Transport and deposition of respira-
777 tory aerosols in models of childhood asthma', *Journal of Aerosol Science* **37**(10), 1234–1257.
- 778 Lu, D., Lee, S. L., Lionberger, R. A., Choi, S., Adams, W., Caramenico, H. N., Chowdhury,
779 B. A., Conner, D. P., Katial, R., Limb, S. et al. (2015), 'International guidelines for bioe-
780 quivalence of locally acting orally inhaled drug products: similarities and differences',
781 *The AAPS journal* **17**(3), 546–557.
- 782 Ma, B. and Lutchen, K. R. (2006), 'An anatomically based hybrid computational model of
783 the human lung and its application to low frequency oscillatory mechanics', *Annals of
784 biomedical engineering* **34**(11), 1691–1704.
- 785 Matuttis, H., Luding, S. and Herrmann, H. (2000), 'Discrete element simulations of dense
786 packings and heaps made of spherical and non-spherical particles', *Powder technology*
787 **109**(1-3), 278–292.
- 788 Mayer, D., Bartz, D., Fischer, J., Ley, S., del Rio, A., Thust, S., Kauczor, H. U. and Heussel,

789 C. P. (2004), 'Hybrid segmentation and virtual bronchoscopy based on CT images', *Acad-*
790 *emic Radiology* **11**(5), 551–565.

791 McQuaid, E. L., Kopel, S. J., Klein, R. B. and Fritz, G. K. (2003), 'Medication adherence in
792 pediatric asthma: reasoning, responsibility, and behavior', *Journal of pediatric psychology*
793 **28**(5), 323–333.

794 Mexichem (n.d.), 'Zephex®134a', Website <http://www.mexichemfluor.com/products/medical/zephex134a/>
795 Accessed 14/05/2019.

796 **URL:** <http://www.mexichemfluor.com/products/medical/zephex134a/>

797 Mitchell, J. P., Nagel, M. W., Wiersema, K. J. and Doyle, C. C. (2003), 'Aerodynamic particle
798 size analysis of aerosols from pressurized metered-dose inhalers: comparison of ander-
799 sen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321
800 aerodynamic particle sizer aerosol spectrometer', *AAPS PharmSciTech* **4**(4), 425–433.

801 Miyawaki, S., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2012), 'Effect of carrier gas
802 properties on aerosol distribution in a CT-based human airway numerical model', *Annals*
803 *of biomedical engineering* **40**(7), 1495–1507.

804 Nardelli, P., Khan, K. A., Corvò, A., Moore, N., Murphy, M. J., Twomey, M., O'Connor,
805 O. J., Kennedy, M. P., Estépar, R. S. J., Maher, M. M. et al. (2015), 'Optimizing parameters
806 of an open-source airway segmentation algorithm using different CT images', *Biomedical*
807 *engineering online* **14**(1), 62.

808 Naseri, A., Shaghaghian, S., Abouali, O. and Ahmadi, G. (2017), 'Numerical investigation of
809 transient transport and deposition of microparticles under unsteady inspiratory flow in
810 human upper airways', *Respiratory physiology & neurobiology* **244**, 56–72.

811 Newman, S. P. (2005), 'Principles of metered-dose inhaler design', *Respiratory Care*
812 **50**(9), 1177–1190.

813 **URL:** <http://rc.rcjournal.com/content/50/9/1177>

814 Nunes, C., Pereira, A. M. and Morais-Almeida, M. (2017), 'Asthma costs and social impact',
815 *Asthma Research and Practice* **3**(1), 1.

- 816 Oakes, J. M., Roth, S. C. and Shadden, S. C. (2018), 'Airflow simulations in infant, child, and
817 adult pulmonary conducting airways', *Annals of biomedical engineering* **46**(3), 498–512.
- 818 Olsson, B. and Bäckman, P. (2018), Mimetikos preludium™: A new pharma-friendly aerosol
819 drug deposition calculator, *in* 'Respiratory Drug Delivery'.
- 820 Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K., Gustavs-
821 son, L. and Hegelund-Myrbäck, T. (2011), Pulmonary drug metabolism, clearance, and
822 absorption, *in* 'Controlled pulmonary drug delivery', Springer, pp. 21–50.
- 823 Ozel, A., Gu, Y., Milioli, C. C., Kolehmainen, J. and Sundaresan, S. (2017), 'Towards fil-
824 tered drag force model for non-cohesive and cohesive particle-gas flows', *Physics of Fluids*
825 **29**(10), 103308.
- 826 Ozel, A., Kolehmainen, J., Radl, S. and Sundaresan, S. (2016), 'Fluid and particle coarsening
827 of drag force for discrete-parcel approach', *Chemical engineering science* **155**, 258–267.
- 828 Poorbahrami, K., Mummy, D. G., Fain, S. B. and Oakes, J. M. (2019), 'Patient-specific model-
829 ing of aerosol delivery in healthy and asthmatic adults', *Journal of Applied Physiology* .
- 830 Poorbahrami, K. and Oakes, J. M. (2019), 'Regional flow and deposition variability in adult
831 female lungs: A numerical simulation pilot study', *Clinical Biomechanics* **66**, 40–49.
- 832 Radl, S. and Sundaresan, S. (2014), 'A drag model for filtered euler–lagrange simulations of
833 clustered gas–particle suspensions', *Chemical engineering science* **117**, 416–425.
- 834 Ring, N., Booth, H., Wilson, C., Hoskins, G., Pinnock, H., Sheikh, A. and Jepson, R.
835 (2015), 'The 'vicious cycle' of personalised asthma action plan implementation in primary
836 care: a qualitative study of patients and health professionals' views', *BMC family practice*
837 **16**(1), 145.
- 838 Robinson, R. J., Snyder, P. and Oldham, M. J. (2007), 'Comparison of particle tracking algo-
839 rithms in commercial CFD packages: sedimentation and diffusion', *Inhalation toxicology*
840 **19**(6-7), 517–531.
- 841 Rubin, B. K. (2007), 'Mucus structure and properties in cystic fibrosis', *Paediatric respiratory*
842 *reviews* **8**(1), 4–7.

- 843 Sagaut, P. (2006), *Large eddy simulation for incompressible flows: an introduction*, Springer Sci-
844 ence & Business Media.
- 845 Sen, Y., Zhang, Y., Qian, Y. and Morgan, M. (2011), A comparison of medical image seg-
846 mentation methods for cerebral aneurysm computational hemodynamics, in '2011 4th In-
847 ternational Conference on Biomedical Engineering and Informatics (BMEI)', Vol. 2, IEEE,
848 pp. 901–904.
- 849 Solomon, P. A., Gehr, P., Bennett, D. H., Phalen, R. F., Méndez, L. B., Rothen-Rutishauser, B.,
850 Clift, M., Brandenberger, C. and Mühlfeld, C. (2012), 'Macroscopic to microscopic scales
851 of particle dosimetry: from source to fate in the body', *Air Quality, Atmosphere & Health*
852 **5**(2), 169–187.
- 853 Sundaresan, S., Ozel, A. and Kolehmainen, J. (2018), 'Toward constitutive models for mo-
854 mentum, species, and energy transport in gas–particle flows', *Annual review of chemical and*
855 *biomolecular engineering* **9**, 61–81.
- 856 Tatsumura, T., Koyama, S., Tsujimoto, M., Kitagawa, M. and Kagamimori, S. (1993), 'Further
857 study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of
858 lung carcinomas: fundamental and clinical', *British journal of cancer* **68**(6), 1146.
- 859 The Global Asthma Network (2018), 'The Global Asthma Report'.
- 860 Usmani, O. S. (2019), 'Choosing the right inhaler for your asthma or COPD patient', *Thera-
861 peutics and clinical risk management* **15**, 461.
- 862 Usmani, O. S., Biddiscombe, M. F. and Barnes, P. J. (2005), 'Regional lung deposition and
863 bronchodilator response as a function of β 2-agonist particle size', *American journal of res-
864 piratory and critical care medicine* **172**(12), 1497–1504.
- 865 Usmani, O. S., Biddiscombe, M. F., Nightingale, J. A., Underwood, S. R. and Barnes, P. J.
866 (2003), 'Effects of bronchodilator particle size in asthmatic patients using monodisperse
867 aerosols', *Journal of Applied Physiology* **95**(5), 2106–2112.
- 868 van Holsbeke, C., De Backer, J., Vos, W. and Marshall, J. (2018), 'Use of functional respiratory
869 imaging to characterize the effect of inhalation profile and particle size on lung deposition

- 870 of inhaled corticosteroid/long-acting β 2-agonists delivered via a pressurized metered-
871 dose inhaler', *Therapeutic advances in respiratory disease* **12**, 1753466618760948.
- 872 Verlet, L. (1967), 'Computer" experiments" on classical fluids. i. thermodynamical properties
873 of lennard-jones molecules', *Physical review* **159**(1), 98.
- 874 Wang, Y., Chu, K. and Yu, A. (2017), Transport and deposition of cohesive pharmaceutical
875 powders in human airway, in 'EPJ Web of Conferences', Vol. 140, EDP Sciences, p. 08004.
- 876 Watanabe, J. and Watanabe, M. (2019), 'Anatomical factors of human respiratory tract influ-
877 encing volume flow rate and number of particles arriving at each bronchus', *Biocybernetics*
878 *and Biomedical Engineering* **39**(2), 526–535.
- 879 Wei, W., Huang, S.-w., Chen, L.-h., Qi, Y., Qiu, Y.-m. and Li, S.-t. (2017), 'Airflow behavior
880 changes in upper airway caused by different head and neck positions: Comparison by
881 computational fluid dynamics', *Journal of biomechanics* **52**, 89–94.
- 882 Weller, H. G., Tabor, G., Jasak, H. and Fureby, C. (1998), 'A tensorial approach to com-
883 putational continuum mechanics using object-oriented techniques', *Computers in physics*
884 **12**(6), 620–631.
- 885 Wittgen, B. P., Kunst, P. W., Van Der Born, K., Van Wijk, A. W., Perkins, W., Pilkiewicz, F. G.,
886 Perez-Soler, R., Nicholson, S., Peters, G. J. and Postmus, P. E. (2007), 'Phase i study of
887 aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung', *Clinical*
888 *cancer research* **13**(8), 2414–2421.
- 889 Xi, J., Berlinski, A., Zhou, Y., Greenberg, B. and Ou, X. (2012), 'Breathing resistance and
890 ultrafine particle deposition in nasal–laryngeal airways of a newborn, an infant, a child,
891 and an adult', *Annals of biomedical engineering* **40**(12), 2579–2595.
- 892 Xi, J., Si, X., Kim, J. W. and Berlinski, A. (2011), 'Simulation of airflow and aerosol deposition
893 in the nasal cavity of a 5-year-old child', *Journal of Aerosol Science* **42**(3), 156–173.
- 894 Yang, J., Sharp, G., Veeraraghavan, H., van Elmpt, W., Dekker, A., Lustberg, T. and Gooding,
895 M. (2017), 'Dataset from lung CT segmentation challenge', *The Cancer Imaging Archive* .

896 Yang, J., Veeraraghavan, H., Armato III, S. G., Farahani, K., Kirby, J. S., Kalpathy-Kramer,
897 J., van Elmpt, W., Dekker, A., Han, X., Feng, X. et al. (2018), 'Autosegmentation for tho-
898 racic radiation treatment planning: A grand challenge at AAPM 2017', *Medical physics*
899 **45**(10), 4568–4581.

900 Zhang, B., Qi, S., Yue, Y., Shen, J., Li, C., Qian, W. and Wu, J. (2018), 'Particle Disposition in
901 the Realistic Airway Tree Models of Subjects with Tracheal Bronchus and COPD', *BioMed*
902 *research international* **2018**.

903 Zhang, Z., Kleinstreuer, C. and Hyun, S. (2012), 'Size-change and deposition of conven-
904 tional and composite cigarette smoke particles during inhalation in a subject-specific air-
905 way model', *Journal of Aerosol Science* **46**, 34–52.

906 Zhang, Z., Kleinstreuer, C. and Kim, C. S. (2009), 'Comparison of analytical and cfd mod-
907 els with regard to micron particle deposition in a human 16-generation tracheobronchial
908 airway model', *Journal of Aerosol Science* **40**(1), 16–28.